Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1488786 | 0.83 | PRMT3 (0.48) | MEN1KMT2APRMT3CARM1PRMT6 | |
| SCHEMBL6142141 | 0.81 | MEN1 (0.43) | MEN1KMT2AALDH1A1 | |
| SCHEMBL14943784 | 0.77 | MEN1 (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL12530372 | 0.77 | PRMT3 (0.42) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL6663432 | 0.76 | MEN1 (0.56) | MEN1KMT2A | |
| SCHEMBL1314528 | 0.76 | MEN1 (0.56) | MEN1KMT2AALDH1A1 | |
| SCHEMBL24744949 | 0.75 | MEN1 (0.39) | MEN1KMT2APRMT3CARM1PRMT6 | |
| SCHEMBL14943799 | 0.74 | MEN1 (0.42) | MEN1KMT2AALDH1A1 | |
| SCHEMBL13397378 | 0.73 | EPHX1 (0.37) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL557434 | 0.72 | MEN1 (0.46) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
| US-11696953-B2 | Poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2023101722-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | MEDECINE INNOVATIONS GROUP INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20210388196-A1 | GENE DELIVERY CARRIER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-16 | — | — | US | disclosed |
| US-11041069-B2 | Gene delivery carrier | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-22 | — | — | US | disclosed |
| US-10544161-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190194444-A1 | GENE DELIVERY CARRIER | POLITECNICO DI MILANO (IT) | 2019-06-27 | — | — | US | disclosed |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190125874-A1 | POLY (BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2019-05-02 | — | — | US | disclosed |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | disclosed |
| WO-2008148754-A2 | MACROCYCLES AND THEIR USES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| WO-2007142986-A2 | AMINOTHIAZOLE DERIVATIVES AND THEIR USES AS ANTIBACTERIAL AGENTS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
| US-7232825-B2 | Phenylaminopyrimidine derivatives and methods of use | CHEN GUOQING P | 2007-06-19 | — | — | US | disclosed |
| US-5236956-A | Compounds for the treatment of urinary incontinence | KABI PHARMACIA AKTIEBOLAG (SE) | 1993-08-17 | — | — | US | disclosed |
| US-5219480-A | ETHYLENE ALPHA-OLEFIN MANNICH BASE VISCOSITY INDEX IMPROVER/DISPERSANT ADDITIVES DERIVED FROM AMINO PHENOLS AND MONOSECONDARY AMINES | EXXON CHEMICAL PATENTS INC. (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0367040-B1 | COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE | Kabi Pharmacia AB (SE) | 1993-04-21 | — | — | EP | disclosed |
| EP-0357215-A1 | Ethylene alpha-olefin mannich base viscosity index improver/dispersant additives | EXXON CHEMICAL PATENTS INC. (US) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | PAICS, UGT1A1, CYP7A1 | MEN1 669/4885KMT2A 3299/4885PRMT3 1423/4885 |
| US-20190194444-A1 | GENE DELIVERY CARRIER | PAICS, PBDC1, BCAT1 | MEN1 3571/4885KMT2A 2017/4885PRMT3 3044/4885 |
| US-10544161-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | MEN1 4562/4885KMT2A 4574/4885PRMT3 1798/4885 |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | LPO, PCNA, BPGM | MEN1 3628/4885KMT2A 4280/4885PRMT3 3653/4885 |
| US-20190125874-A1 | POLY (BETA-AMINO ESTERS) AND USES THEREOF | BCAT1, BCAT2, SNRPE | MEN1 4493/4885KMT2A 2481/4885PRMT3 1882/4885 |
| US-11041069-B2 | Gene delivery carrier | PAICS, PBDC1, BCAT1 | MEN1 3571/4885KMT2A 2017/4885PRMT3 3044/4885 |
| US-20210388196-A1 | GENE DELIVERY CARRIER | PAICS, PBDC1, BCAT1 | MEN1 3571/4885KMT2A 2017/4885PRMT3 3044/4885 |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | TTR, MTPN, CRYAA | MEN1 3220/4885KMT2A 4228/4885PRMT3 3961/4885 |
| US-11696953-B2 | Poly(beta-amino esters) and uses thereof | BCAT1, BCAT2, SNRPE | MEN1 4493/4885KMT2A 2481/4885PRMT3 1882/4885 |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | BAX, BCL2, BAD | MEN1 4734/4885KMT2A 3784/4885PRMT3 1375/4885 |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | MEN1 4562/4885KMT2A 4574/4885PRMT3 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.